Skip to main content

Table 3 Results of budget impact analysis

From: Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran

Year

2023

2024

2025

2026

2027

Iran population

86,369,815

87,406,253

88,455,128

89,516,589

90,928,011

number of patients of CRE

6788

6869

6952

7035

7120

total number of CRE patients who deserve to receive CA or COL

5430

5495

5561

5628

5696

COL market share

0.24

0.25

0.26

0.26

0.27

CA market share

0.01

0.02

0.03

0.04

0.05

Scenario 1(without CA)

598,622

636,466

665,679

686,422

708,170

Scenario 2(with CA)

777,117

853,953

920,706

977,588

1,036,456

Financial impact

178,495

217,487

255,027

291,166

328,287

Financial impact%

29%

34%

38%

42%

46%